IPSS Risk Category Intermediate-2

DrugDrug NameDrug Description
DB15694CedazuridineA cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS).
DB01262DecitabineA chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression.
DB12500FedratinibFedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016]
DrugDrug NamePhaseStatusCount
DB00928Azacitidine1 / 2Completed1
DB15232Telaglenastat1 / 2Completed1